Chest Hospital, Department of Health, Executive Yuan, Tainan; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.
Chest. 2013 Jun;143(6):1725-1732. doi: 10.1378/chest.12-2051.
Sputum samples from patients with non-multidrug-resistant (non-MDR) pulmonary TB may remain smear-positive for acid-fast bacilli (AFB) at the fifth month of anti-TB treatment. However, its significance remains unknown.
From January 2004 to April 2009, there were 5,403 patients with culture-confirmed pulmonary TB from four hospitals in Taiwan. Among them, 116 patients (2.2%) with non-MDR TB whose sputum samples were smear-positive by concentration smear method at the fifth month of treatment were evaluated.
Sputum culture yielded Mycobacterium tuberculosis in 10 patients (8.6%, MTB group), nontuberculous mycobacteria in 23 (19.8%, NTM group), and no growth in the remaining 83 (71.6%, no-growth group). The relapse rate (22%) was higher in the MTB group (P = .01). Four predictors, smear grading ≥ 3+ at the fifth month ("S") (OR, 10.73; 95% CI, 2.67-43.17), no sputum culture conversion on the second month ("C") (OR, 7.16; 95% CI, 1.45-35.44), lack of directly observed therapy ("O") (OR, 6.40; 95% CI, 1.54-26.56), and no radiographic improvement at the fifth month ("R") (OR, 4.18; 95% CI, 1.02-17.10), were associated with viable M tuberculosis (MTB group). An integrated "SCOR" index of 1 point for each positive factor had the best discriminatory power for predicting culture results at the fifth month. If the SCOR index was 0, all smear-positive sputum was culture-negative for M tuberculosis.
Positive sputum smears by a concentrated smear method at the fifth month of treatment in patients with non-MDR TB, especially those with a low SCOR index, may be due to nonviable bacilli and NTM. Careful review of the quality of patient supervision, bacteriologic data, and chest radiography is crucial.
非耐多药(non-MDR)肺结核患者在抗结核治疗的第五个月,其痰标本经浓缩抗酸染色仍可能呈阳性。然而,其意义尚不清楚。
2004 年 1 月至 2009 年 4 月,台湾四家医院共 5403 例培养确诊肺结核患者。其中,116 例(2.2%)非耐多药肺结核患者在治疗第五个月时,浓缩抗酸染色法痰标本阳性,对其进行了评估。
10 例患者(8.6%,MTB 组)痰培养出结核分枝杆菌,23 例患者(19.8%,NTM 组)培养出非结核分枝杆菌,83 例患者(71.6%,无生长组)无细菌生长。MTB 组的复发率(22%)较高(P=.01)。第五个月时的涂片分级≥3+(“S”)(OR,10.73;95%CI,2.67-43.17)、第二个月时痰培养未转为阴性(“C”)(OR,7.16;95%CI,1.45-35.44)、未直接观察治疗(“O”)(OR,6.40;95%CI,1.54-26.56)和第五个月时无影像学改善(“R”)(OR,4.18;95%CI,1.02-17.10)这四个预测因素与有活力的结核分枝杆菌(MTB 组)相关。每个阳性因素的综合“SCOR”指数为 1 分,对预测第五个月的培养结果具有最佳的区分能力。如果 SCOR 指数为 0,则所有痰涂片阳性的标本均培养不出结核分枝杆菌。
非耐多药肺结核患者在治疗第五个月时,浓缩抗酸染色法痰涂片阳性,尤其是 SCOR 指数较低者,可能是由于非活力细菌和非结核分枝杆菌所致。仔细审查患者监督、细菌学数据和胸部影像学质量至关重要。